May 7
ENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectThe Institute for Innovation in Biotechnology (IIB) works in close association with the School of Biological Sciences (SBS) at the University of Auckland, and focuses on industry partnerships to accelerate innovation and develop new models of bioscience enterprise training.
ViewThe Curtin Health Innovation Research Institute (CHIRI) is dedicated to developing new treatments for diseases that more commonly occur with older age.
ViewMurdoch Childrens Research Institute is the preeminent child health research institute in Australia, and is recognised globally for its child health discoveries.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer
Read moreThrough a different lens: How Kath Giles and OncoRes Are Reinventing Breast Cancer Surgery
Read moreENA Respiratory: The Difference Between Chance and Discovery? Knowing What to Do Next.
Read moreMeet Proxima Bio: Australia’s next-generation biotech startup aiming to clean up cancer-causing proteins.
Read more